OIA response: Pembrolizumab and nivolumab data, July to September 2019

Response to a request for information for data on nivolumab and pembrolizumab Special Authorities, for July, August and September 2019.

20 November 2019

[name and contact details redacted]

Dear [name redacted]

REQUEST FOR INFORMATION

Thank you for your request dated 25 October 2019 under the Official Information Act 1982 (OIA).  You asked for updated Special Authority data on pembrolizumab and nivolumab Special Authorities, for July, August and September 2019.

The tables below provide the data you requested.

Pembrolizumab - SA1615, SA1657

Month submitted

Initial Applications

Approvals - initial

Renewal Applications

Approval - Renewal

Total applications

Total approvals

Jul 2019

39

29

51

47

90

76

Aug 2019

35

31

56

53

91

84

Sep 2019

29

26

66

56

95

82

Nivolumab - SA1656, SA1602, SA1617

Month submitted

Initial Applications

Approvals - initial

Renewal Applications

Approval - Renewal

Total applications

Total approvals

Jul 2019

0

0

3

3

3

3

Aug 2019

3

3

1

1

4

4

Sep 2019

0

0

0

0

0

0

We trust that this information answers your queries.  We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely

Alison Hill
Director, Engagement and Implementation